Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454016 | 0.98 | TLR4 (0.50) | TLR4OPRM1OPRL1CYP2C9 | |
| SCHEMBL6451893 | 0.98 | TLR4 (0.50) | TLR4OPRM1OPRL1CYP2C9 | |
| SCHEMBL6451888 | 0.98 | TLR4 (0.50) | TLR4OPRM1OPRL1CYP2C9 | |
| SCHEMBL1666552 | 0.90 | TLR4 (0.51) | TLR4OPRM1OPRL1CYP2C9OPRK1 | |
| SCHEMBL8215701 | 0.90 | TLR4 (0.51) | TLR4OPRM1OPRL1CYP2C9OPRK1 | |
| SCHEMBL1666553 | 0.90 | TLR4 (0.51) | TLR4OPRM1OPRL1CYP2C9OPRK1 | |
| SCHEMBL5599141 | 0.89 | TLR4 (0.46) | TLR4OPRM1OPRL1NOS3NOS1 | |
| SCHEMBL14382045 | 0.89 | TLR4 (0.46) | TLR4OPRM1OPRL1NOS3NOS1 | |
| SCHEMBL5599138 | 0.89 | TLR4 (0.46) | TLR4OPRM1OPRL1NOS3NOS1 | |
| SCHEMBL10837113 | 0.89 | TLR4 (0.46) | TLR4OPRM1OPRL1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108277019-A | A kind of preparation method of trans cvclohexvl base class liquid-crystal compounds | 晶美晟光电材料（南京）有限公司 | 2018-07-13 | — | — | CN | disclosed |
| US-8999197-B2 | Compound having a five-membered ring, the liquid crystal composition and the liquid crystal display device | JNC CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140054499-A1 | COMPOUND HAVING A FIVE-MEMBERED RING, THE LIQUID CRYSTAL COMPOSITION AND THE LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20110309300-A1 | COMPOUND HAVING A FIVE-MEMBERED RING, THE LIQUID CRYSTAL COMPOSITION AND THE LIQUID CRYSTAL DISPLAY DEVICE | CHISSO PETROCHEMICAL CORPORATION (JP) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110309300-A1 | COMPOUND HAVING A FIVE-MEMBERED RING, THE LIQUID CRYSTAL COMPOSITION AND THE LIQUID CRYSTAL DISPLAY DEVICE | CTNND1, HCN1, CTNNA1 | TLR4 3605/4885OPRM1 1326/4885OPRL1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.